2025 · Regular session · House bill
HB5155
HB5155 provides for continuing the maternal opioid misuse model of care for pregnant women with opioid use disorder who are enrolled in Medicaid during pregnancy and after birth, and for their children after birth.
Official caption: Relating to the continuation of the maternal opioid misuse model of care for certain Medicaid recipients.
Official report lists House author(s): Rose, Jones, Jolanda. This does not identify sponsors or amendment drafters.
Bill explanation published · Version and amendment review scope is stated below · Individual amendment records may not be separately annotated.
Bill highlights
Selected points from the published explanation. Follow each point to its source-linked context; conditions and limits may matter.
- HB5155 provides for continuing the maternal opioid misuse model of care for pregnant women with opioid use disorder who are enrolled in Medicaid during pregnancy and after birth, and for their children after birth.
- Funding is conditional.
- Sources: final law, all four sections; official history.
What does it do?
HB5155 provides for continuing the maternal opioid misuse model of care for pregnant women with opioid use disorder who are enrolled in Medicaid during pregnancy and after birth, and for their children after birth. It took effect September 1, 2025; the new section expires September 1, 2029.
Funding is conditional. HHSC must implement the section only if the legislature specifically appropriates money for it. Without that appropriation, HHSC may use other available money but is not required to do so. The bill allows money from the opioid abatement account to be appropriated for this care; it does not itself appropriate a sum or guarantee services to every eligible person. Necessary federal approval may also delay implementation.
Sources: final law, all four sections; official history.
What changed along the way?
The introduced bill proposed continuation through December 1, 2028, a report on benefits and birth outcomes by December 31, 2028, and priority for the model as a recipient of council grants from the opioid abatement trust fund.
The House committee substitute instead used Government Code 547.0007, defined the model by reference to the earlier federal funding authority, extended the expiration to September 1, 2029, removed that report and trust-fund grant priority, and allowed appropriations from the separate opioid abatement account. It also fixed the effective date at September 1 rather than allowing immediate effect. The House committee, engrossed, Senate committee and enrolled operative provisions match. No floor amendments are indexed.
The earlier authority, former Government Code 531.0738, directed HHSC to apply for federal model-of-care money and expired September 1, 2021. HB5155 refers to the model supported under that former section; it does not revive every provision of the 2019 maternal-health bill.
Sources: all text versions; amendment index; introduced proposal; committee substitute; 2019 SB750, section 1.
For the full amendment record, open the official amendment index.
Official bill versions
Compare the published text versions in the official text index. A change is not attributed to a specific amendment here without a verified record.
Who could benefit—and who could bear the costs?
The intended benefit is continuity of care for Medicaid-covered pregnant and postpartum women with opioid use disorder and their children. HHSC gains express authority to continue the model using available funding, including a possible appropriation from the opioid abatement account. The conditional funding rule means continuation cannot be inferred from enactment alone. The final law does not expand Medicaid eligibility or establish an unconditional individual entitlement to treatment.
The May 19, 2025 fiscal note anticipates no significant state or local fiscal impact and assumes costs can be absorbed with existing resources. The April 27 substitute note reaches the same conclusion; the April 21 introduced note assessed the earlier report and trust-fund proposal. These estimates do not demonstrate that treatment has no cost or that money was actually appropriated.
Review boundary: the full final act, history, five versions, amendment index and all three fiscal notes were read. The former federal-application authority and the distinct opioid account/trust-fund provisions were also checked. This review establishes what HB5155 authorizes and conditions, not actual appropriations, federal approvals, service availability or measured health outcomes.
Source: latest fiscal note.
Official sources
- Bill history and latest recorded action
- Bill versions, analyses and fiscal notes
- Action history and votes
- Amendment index
Catalog report retrieved 2026-10-25. Check the official record for corrections or later changes.
